Symbols

ORMP

Oramed·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Ample Liquidity

Significant Net Income Growth

EPS Beats Expectation

RSI Overbought

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ORMP

Oramed Pharmaceuticals Inc.

A developer of oral drug delivery systems

Industry

Pharmaceutical

Established Date

04/12/2002

Listing Date

02/11/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.oramed.com

Security Type

Common stock

Office address

1185 Avenue of the Americas , Third Floor , New York , NY 10036

Business

Engaged in the research and development of innovative drug solutions.

Introduction

Oramed Pharmaceuticals Inc., a Delaware corporation, was incorporated on April 12, 2002. The company is a pharmaceutical company engaged in the development of innovative pharmaceutical solutions, and its technology platform allows oral delivery of therapeutic proteins. The company has developed an oral dosage form designed to withstand the harsh environment of the stomach and effectively deliver active biological insulin or protein. The excipients in the formula are not designed for chemical or biological modification of proteins, and the dosage form is designed for safe ingestion.

Company Financials

EPS

ORMP has released its 2024 Q1 earnings. EPS was reported at 0.04, versus the expected 0.02, beating expectations. The chart below visualizes how ORMP has performed over recent quarters, highlighting trends in earnings surprises.